Vivesto AB (STO:VIVE)
Sweden · Delayed Price · Currency is SEK | Market Cap | 79.27M -35.4% |
| Revenue (ttm) | n/a |
| Net Income | -31.54M |
| EPS | -4.07 |
| Shares Out | 11.07M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,148 |
| Open | 7.21 |
| Previous Close | 7.21 |
| Day's Range | 7.10 - 7.49 |
| 52-Week Range | 7.00 - 27.30 |
| Beta | 0.88 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Vivesto AB Transcript: Study result
Dog and cat top-line studies confirmed safety and tolerability, with no hypersensitivity; canine data showed doubled overall survival versus surgery alone. Next steps include pivotal-study planning, regulatory discussions, manufacturing work and partner outreach.
Vivesto AB Press release: Study result
Vivesto AB issued a press release on October 19, 2026, disclosing material business information to investors.
Vivesto AB Quarterly report: Q2 2026
Vivesto AB has published its Q2 2026 quarterly earnings report on August 13, 2026.
Vivesto AB Quarterly report: Q1 2026
Vivesto AB has published its Q1 2026 quarterly earnings report on May 7, 2026.
Vivesto AB Annual report: Q4 2025
Vivesto AB has published its Q4 2025 annual report on February 27, 2026.
Vivesto AB Quarterly report: Q4 2025
Vivesto AB has published its Q4 2025 quarterly earnings report on February 27, 2026.
Vivesto AB Transcript: DNB Carnegie Småbolagsdag
Recent interim results show Pakalvet doubles median survival in dogs with hemangiosarcoma, while Cantrixil demonstrates strong efficacy in preclinical hematological cancer models. Key studies are set to complete next year, with active partnering efforts underway to accelerate market entry.
Vivesto AB Transcript: Study update
The update highlights a focused oncology strategy with strong interim results for Paccal Vet in dogs and promising early data in cats, as well as preclinical success for Cantrixil in AML. A SEK 53.8M rights issue will fund key studies and partnering efforts, targeting major milestones in 2026.
Vivesto AB Press release: Study update
Vivesto AB issued a press release on November 24, 2025, disclosing material business information to investors.
Vivesto AB Quarterly report: Q3 2025
Vivesto AB has published its Q3 2025 quarterly earnings report on November 20, 2025.